It is made available under a CC-BY-NC-ND 4.0 International license.

- **Third vaccine doses could have indirectly averted >100,000 deaths in the USA by reducing**
- **transmission of the SARS-CoV-2 Delta variant**
- Billy J. Gardner*, A. Marm Kilpatrick*
-
- *Department of Ecology and Evolutionary Biology, University of California, Santa Cruz, Santa*
- *Cruz, California, 95064 USA*
- **To whom correspondence should be addressed: [wjgytc14@gmail.com;](mailto:wjgytc14@gmail.com) akilpatr@ucsc.edu*
- A. Marm Kilpatrick
- 130 McAllister Way
- EE Biology/CBB
- University of California
- Santa Cruz, CA 95060
- **Preprint Server:** medRxiv: https://www.medrxiv.org/content/10.1101/2021.10.25.21265500
- **Classification** Biological Sciences: Applied Biological Sciences
- **Keywords** COVID-19; vaccine effectiveness, surrogates of protection, vaccination; waning
- immunity; herd immunity, modeling

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Abstract

 Vaccination programs often focus on direct protection of individuals against disease and discount reductions in transmission, which can result in preventable disease and death. Initial clinical trials for most COVID-19 vaccines only measured direct protection, and dosing and vaccine selection decisions have, so far, ignored effects on transmission. Here we provide an empirical framework for incorporating indirect effects of COVID-19 vaccination on transmission in a continuous dynamic immune landscape. For the first time, we quantified relationships between neutralizing antibody titers and vaccine effectiveness for both susceptibility (VES) and infectiousness (VEI) and quantified changes in VE with waning and boosting of immunity. We used these relationships to quantify the impact that additional doses of mRNA vaccines (BNT162b2 and mRNA-1273) could have had in reducing transmission and deaths caused by the deadliest SARS-CoV-2 variant, Delta, in Autumn 2021. Neutralizing antibodies waned 8-fold in 2021 over the six months following initial vaccination with mRNA vaccines, which reduced VE^S 33-38% (from 75-81% to 47-54%) and VEI 62-65% (from 47-57% to 16-22%) against the Delta variant. Third doses increased neutralizing antibody titers 13-26-fold, which more than restored VE and reduced the relative risk of transmission 7-10-fold. Administering third doses by 34 September 1, 2021 could have reduced the effective reproductive number R_t by 19%, stopped surges in transmission in many populations, and averted an estimated 111,491 deaths in the United States. Vaccination programs that incorporate effects on transmission in trial design, vaccination frequency, and vaccine choice are needed to address current and future public health challenges.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Significance

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Introduction

 Vaccination is the most effective tool for reducing disease, hospitalizations, and deaths $\frac{1}{5}$ for many infectious diseases $\frac{1}{5}$. Core components of vaccination programs include how to allocate vaccine doses within and between individuals, when to recommend new doses and, when multiple vaccines are available, which vaccines to recommend. In making these decisions and developing new vaccines, public health agencies often focus on the direct impact of vaccines 58 in reducing disease in vaccinated individuals ^{6,7}. For example, the United States Food and Drug Administration guidelines for randomized control trials for COVID-19 vaccines did not include 60 any criteria regarding protection against infection or reductions in infectiousness δ , and, as a result, these weren't measured in the US trials for mRNA vaccines made by Pfizer-BioNTech and Moderna. Similarly, vaccines are often only recommended for subsets of the population at high risk disease severity $\frac{9}{2}$, despite the fact that in many cases, such as pneumococcal disease, 64 vaccines have been shown to reduce transmission .

 Many vaccines can have population-wide benefits by reducing transmission either by reducing susceptibility or reducing infectiousness (i.e. transmission from breakthrough δ ⁷ infections), or both, which indirectly protects additional individuals ¹¹. In these cases, vaccinating individuals who are not at risk of severe disease can reduce severe disease through reductions in transmission 12 . Deploying vaccines to reduce transmission can increase health equity by reducing infection in individuals that lack access to health care, including vaccination, 71 which is a key global challenge 13 . However, determining whether the benefits of deploying vaccines to reduce transmission is warranted requires estimating vaccine effectiveness (VE) for transmission and the potential number of deaths averted for a specific population, which, in turn, depends on the dynamic levels of population immunity for the pathogen in question.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

75 The emergence of the Delta variant (B.1.617.2) of SARS-CoV-2 in 2021 illustrates the 76 potential benefit of using vaccination to reduce transmission. The Delta variant caused a surge of 77 deaths globally, even in populations with high initial two-dose vaccination coverage 14 . This was 78 due, in part, to the higher infectiousness and severity of this virus variant $15,16$, partial immune 179 evasion 17 , and, critically, waning vaccine immunity. Waning immunity was evident in both 80 levels of neutralizing antibodies and studies of vaccine effectiveness, including for severe 81 disease in older individuals $18,19$. To address the surge in COVID-19 in autumn 2021, third 82 vaccine doses were offered to older ages and at risk individuals, but were not initially offered to 83 healthy younger individuals because VE for severe disease in these age groups remained 84 relatively high 2^0 . However, the potential impacts of offering third doses to all individuals to 85 reduce transmission was not considered because of a lack of information on the benefits of 86 indirect protection 2^1 .

87 Here we estimate the potential impact of third doses of mRNA vaccines on population-88 level transmission of the Delta variant in late 2021 and the number of deaths that could have 89 been averted. We first estimated how VE_S and VE_I change over time due to waning and boosting 90 of immunity. Previous work has demonstrated strong correlations between a surrogate measure 91 of protection, neutralizing antibody titers, and VE for symptomatic and severe disease $22-27$, and 92 one study used these relationships to examine the impacts of vaccination for averting disease and 93 . deaths²⁶. Here, we extend this approach by developing the first relationships, for any pathogen, 94 between neutralizing antibody titers and VE_S and VE_I, which are required to estimate the impact 95 of vaccination on transmission. We then quantified relationships between neutralizing antibody 96 titers and time since vaccination, and following boosting with a third dose of mRNA vaccines. 97 We integrated these two relationships to estimate the potential impacts of deploying additional

It is made available under a CC-BY-NC-ND 4.0 International license.

- vaccine doses on the reproductive number of the virus, *Rt,* under multiple scenarios. Finally, we
- estimated the number of Delta infections and deaths that could have been averted in the United
- States in Autumn 2021 by deploying third doses to reduce transmission.
-
- **Results**
- We found very strong relationships between variant- and vaccine-neutralizing antibody
- 104 titer ratios (NATR_{tot}) and VE using 23 estimates of VE_S (susceptibility) and 14 estimates of VE_I
- (infectiousness) across three variants and four vaccines (Figure 1A,B; Table S1). VE^S was higher
- than VE^I across the range of NATRtot observed, but the slope of VE^I was higher (VE increased

107 more rapidly as NATR_{tot} values increased) (Figure 1; Table S1).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

109 **Fig. 1. Vaccine Effectiveness (VE) plotted against variant- and vaccine-specific neutralizing**

131 protection waned (Figure 2C, D).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a CC-BY-NC-ND 4.0 International license.

 Figure 2. Waning of neutralizing antibody titers and VE for susceptibility (VES) and infectiousness (VEI) over time and following boosting with a third dose. Lines show fitted models and ribbons show ± 1 SE (Table S1). A) Neutralizing antibody titers relative to convalescent sera with wild-type (WT) virus, adjusted for the 2.2-fold lower neutralization titers with the Delta variant relative to wild-type virus. B) The same data as in panel A but rescaled relative to the initial peak value (i.e. all lines start at a value of 1) to show relative

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 rates of waning and levels of stabilization (Table S1). C) VE for susceptibility (VES) over time using the patterns of waning in Panel A and the relationships between antibody titers and VE for susceptibility (Figure 1A). D) VE for infectiousness (VEI) over time using the patterns of waning in Panel A and the relationships between antibody titers and VE for infectiousness (Figure 1B). Points in the upper righthand corner of panels C and D, indicated by the black arrows, show the effect of third doses in boosting VE for the BNT162b2 and mRNA-1273 vaccines.

 Next, we examined the impacts of third doses on population-level transmission in the United States via reductions in the reproductive rate of the pathogen, Rt. On September 1, 2021, the average time since vaccination for vaccinated individuals (53.2% of the population) was 4 months (118.3 days) (Figure S1) resulting in average antibody titers waning to less than 22% of peak values. If all doubly vaccinated individuals in the USA received a third dose of an mRNA vaccine that took effect on 1 September 2021 this would have reduced *R^t* by 18.4% (95% CI: 15.0% to 21.8%) from 1.17 to 0.96 (Figure 3D). This would have stopped the strong surge in cases, hospitalizations, and deaths that occurred over the next few months, assuming contact rates and other behaviors didn't change following boosting (see Methods for further details). Notably, using the same number of doses to doubly vaccinate unvaccinated individuals (assuming they were willing to be vaccinated) rather than boost previously vaccinated 169 individuals would have been similarly effective in reducing transmission $(R_t$ would decrease from 1.17 to 0.94 versus 1.17 to 0.96 for using doses for boosting vaccinated individuals) (Figure 171 3D, compare right end of red line to red point labeled " $R_0 = 3.2$, 79.8% vacc., no 3rd doses" on left side). We also explored several other scenarios with varying vaccination and infection rates 173 and contact rates, which showed that the percent reduction in R_t was driven primarily by the

It is made available under a CC-BY-NC-ND 4.0 International license.

- fraction of the population vaccinated, which determined the potential boosting fraction
- (Supplemental Results Text, Figure S2).

 Figure 3. United States population vaccination and infection history over time, population- level vaccine effectiveness against susceptibility (VES) and infectiousness (VEI) over time, 179 **and the relationship between the pathogen effective reproductive number,** R_t **and third dose coverage, as of 1 September, 2021. A) Fraction of the US population that had received**

It is made available under a CC-BY-NC-ND 4.0 International license.

sometimes exceeding 200,000 (Figure S3), and reported deaths sometimes exceeding 2,000/day

199 (Figure 4). However, during this period the estimated R_t for the US population mostly fluctuated

between 0.9 and 1.1 (Figure S3), suggesting that many thousands of deaths could have been

201 prevented if R_t could have been reduced, even marginally. As we just illustrated, boosting the

53.2% of the population that had been vaccinated with a third dose by 1 September, 2021 would

203 have reduced R_t by 18.4% (Figure 3D, red line). This would have reduced the number of Delta

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- deaths by 111,525 (95% CI: 103,819 to 116,641) (Figure 4E, blue shaded region) by averting
- 37,174,963 infections (95% CI: 34,606,246 38,880,500) (Figure 4A, orange shaded region).
- Boosting with third doses could have averted 629.5 (95% CI: 586.0 to 658.3) deaths per million
- vaccine doses administered due to effects on transmission alone.

 Figure 4. Estimated daily infections (A-D) and reported or estimated deaths (E-H) with and without third dose boosting plotted against time in the United States when the Delta SARS- CoV-2 variant was dominant. Black lines in the left panels show the estimated number of infections each day, calculated by deconvolution using the observed daily deaths (dark blue lines in right panels) and the delays between infection and death, and using and an infection fatality ratio (IFR) of 0.003 ²⁹. Deaths from the Delta variant were estimated using **reported deaths and variant fractions based on sequencing data (see Methods). Red lines in left panels show the estimated number of infections with third dose boosting, and light blue lines show the number of deaths resulting from these infections with the timing estimated**

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Discussion

 The indirect effects of vaccination in reducing disease by reducing transmission (via reduced susceptibility or infectiousness) were rarely considered at any stage of COVID-19 vaccination programs, including initial trial design, initial vaccination, and subsequent boosting. We found that boosting population immunity with third vaccine doses could have substantially reduced transmission of the most deadly SARS-CoV-2 variant, Delta, stopped surges, and averted huge numbers of deaths in many populations, including more than 100,000 in the US. We estimated that 629 deaths could have been averted per million vaccine doses which is similar to or higher than the direct effects of COVID-19 vaccination in other studies (93 to 836 deaths 238 per million doses administered $30-33$). However, many countries initially offered third doses only 239 to protect at-risk individuals and only later offered third doses to the general population . Likely as a result, third dose uptake by the general population in most countries was low. It may

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 have been higher if the third dose boosters were immediately and strongly recommended, or 242 mandated for the whole population .

 The approach we developed here provides an empirical framework for estimating the effect of vaccination on transmission in a dynamic immune landscape. The key components are the temporal dynamics of a surrogate of protection neutralizing antibody titers and relationships between neutralizing antibody titers and the two components of transmission: susceptibility and infectiousness. Previous studies have shown that neutralizing antibody titers were strongly 248 correlated with VE for symptomatic disease and severe disease $22-24,26,27$. Here, we significantly advanced this approach by showing that antibody titers were also strongly correlated with VE^S and VEI. This advance is critical for building accurate mathematical models of SARS-CoV-2 transmission as immunity wanes and is boosted with additional vaccine doses or infection. Previous models have assumed VE for transmission was the same as VE for symptomatic 253 disease²⁶, which underestimates susceptibility (the relative risk of infection) and underestimates transmission (Figure S4). A similar empirical framework for estimating the effect of vaccination on transmission could be developed for other pathogens, such as influenza virus, but it would 256 require a surrogate of protection³⁵ and multiple estimates of vaccine efficacy for susceptibility and infectiousness in population with different levels of immunity.

 We found that VE^S and VE^I declined rapidly in the first 3-5 months post-vaccination in BNT162b2 recipients and plateaued after ~6 months, with slower, waning in mRNA-1273 260 recipients, which may or may not be related to long lasting plasma cells $36,37$. These rates of waning suggest that vaccinating individuals multiple times per year would have substantially increased VE for transmission against the Delta variant, and would likely increase VE for transmission for the currently circulating SARS-CoV-2 variants as well. Given the summer

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

surges of COVID-19 hospitalizations that now appear to be a repeatable phenomenon,

 recommending two vaccine doses per year for COVID-19, especially in sensitive settings such as skilled nursing facilities, could provide substantial benefits.

 We found third vaccine doses could have reduced Delta deaths dramatically, but the impact depended on the timing when doses were administered. Rolling out third doses by September 1 would have averted an additional 37,951 Delta deaths in the US compared to waiting until October 1, which emphasizes the timeliness of vaccinations. Two related factors made a September 1 rollout especially impactful. First, infections were near their peak in September. Second, R^t was below 1.03 from September 1 until late November when the Omicron 273 variant began to invade. The potential reduction in R_t due to third doses (18.4%) was sufficient 274 to reduce R_t well below 1 which would have driven Delta infections and deaths down rapidly (Figure 4). Administering third doses later would have averted fewer deaths caused by the Delta variant (but may have averted additional infections and deaths caused by the Omicron variant).

 Our study has several limitations. First, our analyses use population averages for 278 estimates of VE_S and VE_I and ignore age-specific variation among individuals, as well as other factors. Age-specific patterns of contact, disease severity, and immunity can play a key role in 280 shaping epidemics . We also assumed well-mixed populations in calculating reductions in the 281 reproductive number R_t . A targeted vaccination approach would be more effective than that 282 outlined here if highly connected individuals could be targeted for third doses . Third, our 283 calculations for the reductions in R_t with third doses were based on neutralizing antibody titers one month after the administration of a third dose. Neutralizing antibody titers also decay 285 following third doses, but the decay rate is much slower than after second doses , suggesting 286 that substantial reductions in R_t from third doses would persist for many months, as we assumed

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 here. Fourth, our analyses were focused on population characteristics in the US in late 2021 and vaccine effectiveness against the Delta variant because data were available for quantifying immunity in populations at this time. The current impact of vaccine doses on transmission of SARS-CoV-2 is more difficult to quantify with currently available data, due to a more complex immune landscape, with most people having been infected several times with multiple virus variants and vaccinated with multiple vaccine types, and the variant composition of SARS-CoV- 2 viruses is sometimes diverse and changes frequently. Determining the current benefit of vaccination for reducing transmission would require estimates of the distribution of neutralizing antibody titers against currently circulating viruses in target populations, and measuring increases in antibody titers following vaccination. Finally, quantifying the impact of vaccination in reducing deaths due to reduced transmission does not take into account additional benefits of reduced infections including reduced absenteeism from work and school and reduced cases of long COVID. The total benefits of reduced transmission may outweigh the costs of administering additional vaccine doses in many populations.

 In summary, we showed that the indirect benefits of vaccination in reducing transmission can lead to a huge number of deaths averted. In addition, reductions in transmission increase health equity by reducing infection in individuals that lack access to vaccination. Quantifying vaccine impacts on transmission should be an integral part of developing new vaccines, and estimates of reductions in transmission should be used for planning vaccination strategies, including vaccine selection, targeting, and vaccination schedules.

Methods

Relative neutralizing antibody titers by variant, vaccine dose and with waning

It is made available under a CC-BY-NC-ND 4.0 International license.

VE for susceptibility and infectiousness

 We collected VE estimates for susceptibility and infectiousness for SARS-CoV-2 from 328 the literature, including a systematic living review , and categorized each study by vaccine, time since vaccination, and variant type (wild-type/D614G, Alpha, Delta). We excluded estimates where the virus variant could not be determined. For estimates of VES, we only included studies where the endpoint was "all infections" (often measured using frequent testing or serology) and excluded studies where the endpoint was "any infection" because "any

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 infection" studies do not capture all infections and include an unknown fraction of asymptomatic infections. Studies of VEI, or transmission given infection, usually compared secondary attack rates in households by vaccination status of the index case.

 To fit a relationship between VE and NATR, we needed estimates of the number of infections in the vaccine and control groups. However, most studies did not report the number of infections; however, all reported a VE and 95% CI. We estimated the effective number of infected individuals in the control group (I_c) and the effective number of infected individuals in the vaccine group (I_v) for each study by determining the number of each needed to match the mean and 95% CI given in a study. We held the effective number of individuals in the control 342 group (N_c) and vaccine group (N_v) constant at 1,000,000 because the 95% CI was invariant to variation in these values for observed incidence values. We used a maximum value of 1000 $\frac{344}{4}$ infections in the control group (I_c) to reduce the undue leverage of some very large studies $\frac{44}{4}$.

Relationships between VE and neutralizing antibody titers by vaccine and variant

 We modeled the relationship between VE and total neutralizing antibody titer ratios (NATR_{tot}) using ²⁴:

$$
349 \tVE = 1 - \frac{1}{1 + e^{-(c_0 + c_1 \log_2(NATR_{tot}))}}
$$
(1)

 We estimated the coefficients c⁰ and c¹ separately for the two endpoints, susceptibility and infectiousness, by maximizing the likelihood of observing the data underlying the VE estimates: the number of infections in the control group, I_c, and vaccine group, I_v, for each study. The 353 likelihood was the product of two binomial distributions with N_c and N_v individuals:

354
$$
L(N_c, I_c, N_v, I_v \mid NATR_{tot}, b_s, c_0, c_1) = Bi(N_c, I_c, b_s)^* Bi(N_v, I_v, b_s^* VE)
$$
 (2)

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Vaccine effectiveness over time

 We estimated VE^S and VE^I in the US for each day from January 1, 2021 to December 13, 2021 for three subpopulations: previously infected and unvaccinated, twice vaccinated and no previous infection, and twice vaccinated and previously infected (hybrid immunity), the timing of prior infections and vaccinations (Figure S1), and the relationships between neutralizing 369 antibody titers and VE_S and VE_I. We estimated the timing of infections using reported deaths 48 and deconvolution, using the distributions for the delays between infection and death (i.e. infection to shedding, shedding to symptom onset, symptom onset to hospitalization, and 372 hospitalization to death) (Table S6) using the deconvolve package in R⁴⁵. For each day, we estimated VE^S and VE^I in each subpopulation against each circulating variant based on the timing of infections and vaccinations, accounting for the waning that occurred in each subpopulation on that date using the fitted model for the relationship between neutralizing 376 antibodies and time since infection and vaccination. We used sequencing data from GISAID 29,46 (offset by 9 days to account for the average delay between infection and reporting date) in the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 US to get a variant-averaged estimate of VE^S and VE^I in each subpopulation for each day using a weighted mean where weights were the observed variant frequency each day. We then estimated a population-wide VE for each day using estimates for the fraction of the population in five subpopulations: fully susceptible, third-dose boosted, and the three subpopulations described above.

The impact of third doses on the reproductive number, R^t

 We used patterns of waning and boosting of neutralizing antibody titers to estimate the impact of providing additional doses of mRNA vaccines to increasing fractions of vaccinated individuals in the USA and other populations on the reproductive number, *Rt*, of the Delta variant of SARS-CoV-2, at four time points in autumn 2021; Sept 1, Oct 1, Nov 1, and Dec 1 (Table S_4). R_t is the average number of secondary cases that each case infects and is equal to the basic reproductive number for a pathogen in a fully susceptible population, *R0*, multiplied by the fraction of the population that is susceptible (i.e. not immune from vaccination or previous infection).

393 We examined the effect of boosting vaccinated individuals with a third dose on R_t by considering five scenarios which were combinations of vaccination, previous infection and contact rates that span the range of circumstances in many countries in late 2021. The five scenarios (with fraction vaccinated and previously infected shown for 1 September 2021) and rationale were (Table S4):

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 We estimated the fraction of the population that was susceptible using data on the fraction of the population that had been vaccinated or infected or both. We first split each population into 417 three groups based on vaccination status: fraction unvaccinated, f_U , fraction vaccinated, f_V , with two doses of either BNT162b2 or mRNA-1273, and fraction boosted with a third dose of the 419 same vaccine used for the primary series, f_B ($f_U+f_V+f_B=1$). We calculated the fraction of people 420 in the USA receiving BNT162b2 and mRNA-1273 from vaccination records ⁴⁷. We estimated the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

421 timing of infections using deconvolution of deaths as described above and calculated the number 422 of infections by dividing deaths by an estimate of the infection fatality ratio (IFR) across of 2020-21 of 0.003²⁹; the results were not sensitive to moderate variation in this estimate. We also 424 examined estimating infections using cases and an infection/case ratio of 4.0⁴⁸ which produced a 425 lower estimate of total infections, and the reduction in R_t with third dose boosting and deaths 426 averted were very similar to the death-deconvolution and IFR method. We estimated the fraction 427 of unvaccinated or vaccinated individuals that had been previously infected using the ratios of 428 cases in these two groups over time in the USA 49 (Figure S5). We used vaccination and 429 infection data to calculate the fraction of people previously infected among unvaccinated, f_{PU}, 430 and vaccinated, f_{PV} individuals (Table S4). We used rates of waning of antibody titers and data 431 on the timing of vaccination and infection from the USA and New Zealand 47 for US and New 432 Zealand scenarios, respectively, to estimate the distribution of NATR_{tot} in populations for the 433 four time points in autumn 2021. We used the distributions of NATRtot to estimate the relative 434 susceptibility, 1-VES, (Figure 1A) and relative infectiousness, 1-VEI, (Figure 1B) for the 435 population in each of four groups: unvaccinated and previously infected (VE_{SP} and VE_{IP}), 436 vaccinated twice and no previous infection (VESV and VEIV), vaccinated three times or boosted 437 (VE_{SB} and VE_{IB}), and vaccinated and infected or hybrid immunity (VE_{SH} and VE_{IH}), all with 438 appropriate adjustments for waning antibody titers (see below). We used these estimates of VE 439 to calculate R_t for populations composed of different fractions of five groups: never infected 440 unvaccinated $(1-f_{PU})f_U$, previously infected unvaccinated f_{PfU}, previously uninfected vaccinated 441 with two doses (1-fpv)fv, previously infected and vaccinated with two doses fpvfv, and boosted 442 with a third dose, regardless of previous infection, f_B :

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

443
$$
R_f = R_0 [(1-f_{PU})f_U + f_{PU}f_U(1-VE_{SP})(1-VE_{IP})+(1-f_{PV})f_V(1-VE_{SV})(1-VE_{IV})+(f_{PV}f_V)(1-VE_{SH})(1-VE_{IH})]
$$

444 VE_{HH} +(f_B)(1-VE_{SB})(1-VE_{IB})] (3)

 Note that in equation (3) the VE values for each population are integrated across the 446 distribution of NATR_{tot} values for that group, and the distribution of NATR_{tot} values in each group reflects the timing of vaccination and infection on a daily timestep. We used the scenario estimates of the fraction of population with different types of immunity

(with timing matched to vaccination and infection and waning as described above) for

450 susceptibility and infectiousness to estimate values of R_t under each scenario at the four time

points in autumn 2021 (Sept. 1, Oct. 1, Nov. 1, and Dec. 1; Table S4). We calculated 95% CIs

for predicted values of R_t that incorporated uncertainty in the relationship between time since

vaccination or infection and NATRistatus, uncertainty in the relationships between neutralizing

antibody titers and VE^S and VEI, as well as uncertainty in NATRvac and NATRvar (Figures 1 and

S2).

The impact of third doses on infections and deaths caused by the Delta variant

 We estimated the timing of the infections that gave rise to observed deaths and total infections in the United States in autumn 2021 using deconvolution as described above. We used -460 SARS-CoV-2 sequencing data ^{29,46} to estimate the daily fraction of all infections that were caused by the Delta variant. We estimated the reduction in Delta infections if third-dose boosters were given to all fully vaccinated individuals at four time points in autumn 2021. We assumed the additional doses would take full effect simultaneously on Sept. 1, Oct. 1, Nov. 1, or Dec. 1. We estimated the number of Delta infections that would have occurred if third doses had been

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- We received funding from the National Science Foundation (DEB- 1911853, 1115895, and
- 1717498) and the California Department of Health.

- **References**
- 1 Allen A. Vaccine—the controversial story of medicine's greatest lifesaver. New York, NY: W.W. Norton & Co., 2007.
- 2 Minor PD. Live attenuated vaccines: Historical successes and current challenges. *Virology* 2015; **479–480**: 379–92.
- 3 Greenwood B. The contribution of vaccination to global health: past, present and future. *Phil Trans R Soc B* 2014; **369**: 20130433.
- 4 Hinman AR, Orenstein WA, Schuchat A. Vaccine-preventable diseases, immunizations, and MMWR--1961-2011. *MMWR Suppl* 2011; **60**: 49–57.
- 5 Roush SW. Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States. *JAMA* 2007; **298**: 2155.
- 6 Hudgens MG, Gilbert PB, Self SG. Endpoints in vaccine trials. *Stat Methods Med Res* 2004; **13**: 89–114.
- 7 Li X, Mukandavire C, Cucunubá ZM, *et al.* Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. *The Lancet* 2021; **397**: 398–408.
- 8 COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19- developing-drugs-and-biological-products-treatment-or-prevention.
- 9 CDC. Child and Adolescent Immunization Schedule by Age. 2023. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html.
- 10CDC. Direct and indirect effects of routine vaccination of children with 7-valent
- pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United
- States, 1998-2003. 2005. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm.
- 11Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. 1985.
- 12Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. *Science* 2009; **325**: 1705–8.
- 13Marmot M. Achieving health equity: from root causes to fair outcomes. *The Lancet* 2007; **370**: 1153–63.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 14Walker J, Grubaugh ND, Gonsalves G, Pitzer V, Rizvi Z. One Million and Counting:
- Estimates of Deaths in the United States from Ancestral SARS-CoV-2 and Variants. *medRxiv* 2022; : 2022.05.31.22275835.
- 15Campbell F, Archer B, Laurenson-Schafer H, *et al.* Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Eurosurveillance* 2021; **26**.
- DOI:10.2807/1560-7917.ES.2021.26.24.2100509.
- 16Elliott P, Haw D, Wang H, *et al.* Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. *Science* 2021; **374**: eabl9551.
- 17Planas D, Veyer D, Baidaliuk A, *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* 2021; **596**: 276–80.
- 18Lustig Y, Zuckerman N, Nemet I, *et al.* Neutralising capacity against Delta (B.1.617.2) and
- other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in
- health care workers, Israel. *Eurosurveillance* 2021; **26**. DOI:10.2807/1560-
- 7917.ES.2021.26.26.2100557.
- 19Wu K, Werner AP, Moliva JI, *et al.* mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. *bioRxiv* 2021; published online Jan 25. DOI:10.1101/2021.01.25.427948.
- 20Bar-On YM, Goldberg Y, Mandel M, *et al.* Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19. *medRxiv* 2021; published online Oct 7. DOI:10.1101/2021.10.07.21264626.
- 21Krause PR, Fleming TR, Peto R, *et al.* Considerations in boosting COVID-19 vaccine immune responses. *The Lancet* 2021; **398**: 1377–80.
- 22Cromer D, Steain M, Reynaldi A, *et al.* Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe* 2022; **3**: e52–61.
- 23Cromer D, Steain M, Reynaldi A, *et al.* Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. *Nat Commun* 2023; **14**: 1633.
- 24Gardner BJ, Kilpatrick AM. Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers. *Viruses* 2024; **16**. DOI:10.3390/v16030479.
- 25Hogan AB, Doohan P, Wu SL, *et al.* Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach. *Nat Commun* 2023; **14**: 4325.
- 26Hogan AB, Wu SL, Toor J, *et al.* Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study. *PLoS Med* 2023; **20**: e1004195.

It is made available under a CC-BY-NC-ND 4.0 International license.

 27Khoury DS, Cromer D, Reynaldi A, *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; **27**: 1205–11. 28Falsey AR, Frenck RW, Walsh EE, *et al.* SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med* 2021; **385**: 1627–9. 29Kilpatrick AM. Ecological and Evolutionary Insights About Emerging Infectious Diseases from the COVID-19 Pandemic. *Annu Rev Ecol Evol Syst* 2023; **54**: 171–93. 30Kayano T, Sasanami M, Kobayashi T, *et al.* Number of averted COVID-19 cases and deaths attributable to reduced risk in vaccinated individuals in Japan. *The Lancet Regional Health - Western Pacific* 2022; **28**: 100571. 31Haas EJ, McLaughlin JM, Khan F, *et al.* Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. *The Lancet Infectious Diseases* 2022; **22**: 357–66. 32Santos CVBD, Noronha TGD, Werneck GL, Struchiner CJ, Villela DAM. Estimated COVID- 19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: a retrospective observational study. *The Lancet Regional Health - Americas* 2023; **17**: 100418. 33Mendes D, Chapman R, Gal P, *et al.* Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021. *Journal of Medical Economics* 2022; **25**: 1039–50. 34Mello MM, Opel DJ, Benjamin RM, *et al.* Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. *The Lancet* 2022; **400**: 535–8. 35Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N. The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines? *Human Vaccines & Immunotherapeutics* 2018; **14**: 647–56. 36Nguyen DC, Hentenaar IT, Morrison-Porter A, *et al.* SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination. *Nat Med* 2024; published online Sept 27. DOI:10.1038/s41591-024-03278-y. 37Schulz AR, Fiebig L, Hirseland H, *et al.* SARS-CoV-2 specific plasma cells acquire long- lived phenotypes in human bone marrow. *eBioMedicine* 2023; **95**: 104735. 38Yuan H-Y, Baguelin M, Kwok KO, Arinaminpathy N, Van Leeuwen E, Riley S. The impact of stratified immunity on the transmission dynamics of influenza. *Epidemics* 2017; **20**: 84–93. 39Firth JA, Hellewell J, Klepac P, Kissler S, Kucharski AJ, Spurgin LG. Using a real-world network to model localized COVID-19 control strategies. *Nat Med* 2020; **26**: 1616–22.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 40Gilboa M, Regev-Yochay G, Mandelboim M, *et al.* Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. *JAMA*
- *Netw Open* 2022; **5**: e2231778.
- 41Chu L, Vrbicky K, Montefiori D, *et al.* Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. *Nat Med* 2022; **28**: 1042–9.
- 42Goel RR, Painter MM, Apostolidis SA, *et al.* mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. *Science* 2021; **374**: abm0829.
- 43Higdon MM, Wahl B, Jones CB, *et al.* A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. *Open Forum Infectious Diseases* 2022; **9**: ofac138.
- 44Lewnard JA, Patel MM, Jewell NP, *et al.* Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines. *Epidemiology* 2021; **32**: 508–17.

 45Lewnard JA, Liu VX, Jackson ML, *et al.* Incidence, clinical outcomes, and transmission dynamics of hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in California and Washington, United States: a prospective cohort study. 2020; published online April 16. DOI:10.1101/2020.04.12.20062943.

- 46Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data from vision to reality. *Eurosurveillance* 2017; **22**. DOI:10.2807/1560-7917.ES.2017.22.13.30494.
- 47Mathieu E, Ritchie H, Rodés-Guirao L, *et al.* Coronavirus Pandemic (COVID-19). Our World in Data. 2020.
- 48CDC. Estimated COVID-19 Burden. 2021. https://www.cdc.gov/coronavirus/2019- ncov/cases-updates/burden.html.
- 49COVID Data Tracker. CDC. 2021. https://covid.cdc.gov/covid-data-tracker/.
- 50Park SW, Sun K, Abbott S, *et al.* Inferring the differences in incubation-period and
- generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2.
- *Proceedings of the National Academy of Sciences* 2023; **120**: e2221887120.